Fasching, P. A., Fehm, T., Kellner, S., de Waal, J., Rezal, M., Baler, B., Baake, G., Kolberg, H. -C, Guggenberger, M., Warm, N., Harbeck, N., Wuerstlein, R., Deuker, J. -U, Dall, P., Richter, B., Wachsmann, G., Brucker, C., Siebers, J. W., Fersis, N., Kuhn, T., Wolf, C., Vollert, H. -W, Breitbach, G. -P, Janni, W., Landthaler, R., Kohls, A., Rezek, D., Nosslet, T., Fischer, G., Henschen, S., Praetz, T., Heyl, V., Kuehn, T., Krauss, T., Thomssen, C., Kuemmel, S., Hohn, A., Tesch, H., Mundhenke, C., Hein, A., Rauh, C., Bayer, C. M., Jacob, A., Schmidt, K., Belleville, E., Hadji, P., Wallwiener, D., Grischice, E. -M, Beckmann, M. W. and Brucker, S. Y. (2014). Evaluation of Therapy Management and Patient Compliance in Postmenopausal Patients with Hormone Receptor-positive Breast Cancer Receiving Letrozole Treatment: The EvaluateTM Study. Geburtshilfe Frauenheilkd., 74 (12). S. 1137 - 1144. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1438-8804

Full text not available from this repository.

Abstract

Introduction: The EvaluateTM study (Evaluation of therapy management and patient compliance in postmenopausal hormone receptor-positive breast cancer patients receiving letrozole treatment) is a prospective, non-interventional study for the assessment of therapy management and compliance in the routine care of postmenopausal women with invasive hormone receptor-positive breast cancer receiving letrozole. The parameters for inclusion in the study are presented and discussed here. Material and Methods: Between January 2008 and December 2009 a total of 5045 patients in 310 study centers were recruited to the EvaluateTM study. Inclusion criteria were hormone receptor-positive breast cancer and adjuvant treatment or metastasis. 373 patients were excluded from the analysis for various reasons. Results: A total of 4420 patients receiving adjuvant treatment and 252 patients with metastasis receiving palliative treatment were included in the study. For 4181 patients receiving adjuvant treatment, treatment with the aromatase inhibitor letrozole commenced immediately after surgery (upfront). Two hundred patients had initially received tamoxifen and started aromatase inhibitor treatment with letrozole at 1-5 years after diagnosis (switch), und 39 patients only commenced letrozole treatment 5-10 years after diagnosis (extended endocrine therapy). Patient and tumor characteristics were within expected ranges, as were comorbidities and concurrent medication. Conclusion: The data from the EvaluateTM study will offer a good overview of therapy management in the routine care of postmenopausal women with hormone receptor-positive breast cancer. Planned analyses will look at therapy compliance and patient satisfaction with how information is conveyed and the contents of the conveyed information.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Fasching, P. A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Fehm, T.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kellner, S.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
de Waal, J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Rezal, M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Baler, B.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Baake, G.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kolberg, H. -CUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Guggenberger, M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Warm, N.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Harbeck, N.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Wuerstlein, R.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Deuker, J. -UUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Dall, P.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Richter, B.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Wachsmann, G.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Brucker, C.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Siebers, J. W.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Fersis, N.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kuhn, T.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Wolf, C.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Vollert, H. -WUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Breitbach, G. -PUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Janni, W.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Landthaler, R.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kohls, A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Rezek, D.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Nosslet, T.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Fischer, G.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Henschen, S.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Praetz, T.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Heyl, V.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kuehn, T.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Krauss, T.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Thomssen, C.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kuemmel, S.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hohn, A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Tesch, H.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Mundhenke, C.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hein, A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Rauh, C.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Bayer, C. M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Jacob, A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schmidt, K.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Belleville, E.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hadji, P.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Wallwiener, D.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Grischice, E. -MUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Beckmann, M. W.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Brucker, S. Y.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-421296
DOI: 10.1055/s-0034-1383401
Journal or Publication Title: Geburtshilfe Frauenheilkd.
Volume: 74
Number: 12
Page Range: S. 1137 - 1144
Date: 2014
Publisher: GEORG THIEME VERLAG KG
Place of Publication: STUTTGART
ISSN: 1438-8804
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
ADJUVANT ENDOCRINE THERAPY; PATIENTS ANASTROZOLE COMPLIANCE; RANDOMIZED-TRIAL; TAMOXIFEN THERAPY; PACT PROGRAM; WOMEN; EXEMESTANE; COMBINATION; ADHERENCEMultiple languages
Obstetrics & GynecologyMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/42129

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item